Prevymis Injection

  • Viral infections

Prevymis Injection Generic Name & Formulations

General Description

Letermovir 240mg/12mL, 480mg/24mL; soln for IV infusion after dilution; contains hydroxypropyl betadex; preservative-free.

Pharmacological Class

CMV DNA terminase complex inhibitor.

See Also

How Supplied

Tabs—14, 28; Single-dose vial—1


Generic Availability


Prevymis Injection Indications


Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).

Prevymis Injection Dosage and Administration


Give as IV infusion over 1hr; do not give as IV bolus. Start between Days 0 and 28 post-transplantation (before or after engraftment) and continue through Day 100 post-transplant. 480mg once daily. Concomitant cyclosporine: 240mg once daily. Switch to oral therapy as soon as able to take oral meds.


<18yrs: not established.

Prevymis Injection Contraindications


Concomitant pimozide, ergot alkaloids. Concomitant pitavastatin, simvastatin when co-administered with cyclosporine.

Prevymis Injection Boxed Warnings

Not Applicable

Prevymis Injection Warnings/Precautions


Monitor for CMV reactivation after therapy completion. Renal impairment (CrCl <50mL/min): closely monitor serum creatinine (in IV use). Severe hepatic impairment (Child-Pugh C): not recommended. Pregnancy. Nursing mothers.

Prevymis Injection Pharmacokinetics

See Literature

Prevymis Injection Interactions


See Contraindications. Specific interactions with cyclosporine: see full labeling. Concomitant inducers of P-gp and/or UGT, nafcillin, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, thioridazine, bosentan, St. John's wort, efavirenz, etravirine, nevirapine, pitavastatin, simvastatin, modafinil: not recommended. May be potentiated by OATP1B1/3 inhibitors. Potentiates CYP3A substrates (eg, midazolam, alfentanil, fentanyl, quinidine), OATP1B1/3 substrates: see full labeling for dose adjustment. Concomitant amiodarone, voriconazole, sirolimus, tacrolimus, omeprazole, pantoprazole: monitor frequently and adjust dose if necessary. Monitor INR with warfarin. Concomitant glyburide, repaglinide, rosiglitazone: monitor glucose levels; avoid repaglinide if co-administered with cyclosporine. Concomitant atorvastatin (max 20mg daily): monitor closely; avoid if co-administered with cyclosporine. Concomitant fluvastatin, lovastatin, pravastatin, rosuvastatin: monitor and reduce statin dose if necessary; avoid lovastatin if co-administered with cyclosporine.

Prevymis Injection Adverse Reactions

Adverse Reactions

Nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, abdominal pain, lab abnormalities.

Prevymis Injection Clinical Trials

See Literature

Prevymis Injection Note

Not Applicable

Prevymis Injection Patient Counseling

See Literature